November 2023 in “Journal of Skin and Sexually Transmitted Diseases” Gefitinib can cause scalp skin issues and permanent hair loss.
November 2023 in “Expert Opinion on Pharmacotherapy” Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
August 2023 in “Journal of inflammation research” An elderly Chinese man lost all his hair after taking a new heart medication.
July 2023 in “World Journal of Biology Pharmacy and Health Sciences” Trazodone and Chlorpromazine might help treat sexual dysfunction from finasteride and SSRIs.
June 2023 in “Journal of Natural Remedies” Hibiscus rosa sinensis may help manage hair loss.
June 2023 in “Journal of Clinical Oncology” CDK4/6 inhibitors may cause hair loss in breast cancer patients.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
October 2022 in “Revista Eletrônica Acervo Médico” 5-Alpha-Reductase Inhibitors can cause negative side effects.
July 2022 in “Journal of Investigative Dermatology” Dkk4 is necessary for the initial development and arrangement of hair follicles.
July 2022 in “Journal of Investigative Dermatology”
April 2022 in “Molecules” Teak leaf extract contains compounds that could help treat hair loss.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
October 2021 in “Journal of Investigative Dermatology” Dkk4 protein is necessary for the proper development and arrangement of hair follicles.
August 2021 in “International Journal of Research in Dermatology” Amarantha hair oil contains β-sitosterol, which helps promote hair growth.
A girl with Crohn's disease developed hair loss due to her increased medication, a rare side effect seen in some children.
January 2021 in “Figshare” Finasteride's molecular properties and active sites were identified using computational methods.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
February 2020 in “Definitions” 5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
January 2019 in “Urology Practice” Urologists prescribe newer medications more often than primary care physicians, who could benefit from more education on treatment options.
June 2018 in “The Journal of Sexual Medicine” Finasteride does not negatively affect male reproductive function.
April 2018 in “The Journal of Urology” Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
November 2017 in “International journal of family & community medicine” A man's low testosterone and related symptoms improved after he stopped taking hair loss drugs.
November 2017 in “JAMA internal medicine” Women also use 5α-reductase inhibitors, and their effects differ from men.
April 2017 in “Austin Journal of Cancer and Clinical Research” 5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
April 2017 in “Journal of Investigative Dermatology” SM04755 may be an effective topical treatment for psoriasis.